Stéphane Bancel

Founding CEO, Moderna
Boston, Massachusetts,United States
Find Stéphane Bancel's Email
Find Stéphane Bancel's Phone

Who Is Stéphane Bancel?

Total Experience43 years
CompanyModerna
CountryUnited States

Stéphane Bancel is a French business executive and the Chief Executive Officer of the American biotechnology company Moderna. With a background in chemical engineering, computer science, and business, he has leveraged his diverse expertise to lead Moderna from a research-stage company to a global leader in mRNA technology. Before joining Moderna in 2011, Bancel served as CEO of the French diagnostics company bioMérieux and held several management positions at Eli Lilly and Company. He is most widely recognized for his pivotal role in steering Moderna through the rapid development and successful launch of its COVID-19 vaccine, Spikevax, which has had a profound impact on global public health.

Stéphane Bancel LinkedIn pageCompany Website

How Did Stéphane Bancel's Career Path Shape Their Journey?

Stéphane Bancel's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:

Moderna - Founding CEO(2011 to Present)
QIAGEN - Board Director(2013 to Present)
Knome Inc - Board Director(2008 to 2013)
bioMerieux - CEO(2007 to 2011)
Eli Lilly - Country Manager, Belgium(2004 to 2006)
Eli Lilly & Co - Executive Director, Global Manufacturing Strategy and Global Supply Chain(2003 to 2004)
Eli Lilly U.K. - Manager, Supply Chain(2000 to 2002)
bioMerieux Asia-Pacific - Sales & Marketing Director(1995 to 1998)

What Are Stéphane Bancel's Key Achievements?

Pioneering the mRNA COVID-19 Vaccine

Led Moderna in the unprecedentedly rapid development and global rollout of Spikevax (mRNA-1273), one of the first and most effective vaccines against COVID-19. This achievement not only saved countless lives but also validated the immense potential of the mRNA platform for future vaccines and therapeutics.

Transforming Moderna into a Biotech Powerhouse

As CEO since 2011, he built Moderna from a promising startup into a multi-billion dollar, commercial-stage company. He was instrumental in securing massive funding, establishing a robust pipeline of mRNA candidates, and scaling manufacturing capabilities.

Chevalier de la Légion d'Honneur

Awarded the Knight of the Legion of Honor, France's highest order of merit, in 2021 for his contributions to global health during the pandemic.

Fortune's Businessperson of the Year

Recognized by Fortune magazine as a top Businessperson of the Year in 2021, highlighting his exceptional leadership, innovation, and impact on both business and society.

What's Stéphane Bancel's Educational Background?

MBA

Harvard Business School - Year 1999

Master of Engineering (M.Eng.), Chemical and Biomolecular Engineering

ecole centrale paris - Year 1992

M. Sc., Chemical Engineering

University of Minnesota - Year 1994

Buying Intent Signals for Stéphane Bancel

Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance

Company Overview

Moderna
Total employees5900
HeadquartersCambridge
Founded2010

Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. From an end-user perspective, the company is best known for developing one of the first and most effective COVID-19 vaccines, Spikevax, which has been crucial in the global fight against the pandemic. The company's core mission is to leverage its innovative mRNA platform to create a new generation of transformative medicines for a wide range of diseases, including infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. For consumers and patients, Moderna represents the cutting edge of science, offering hope for previously untreatable conditions by using the body's own cells to produce therapeutic proteins.

Company Website
Moderna Stock Information
Moderna, Inc. is listed on the NASDAQ under the ticker symbol MRNA. The company went public on December 7, 2018

Highperformr's free tools for company research

Find contact info

Get verified emails, phone numbers, and LinkedIn profile details

Find similar contacts

Discover contacts with similar roles, seniority, or companies

Perform deep contact research

Uncover insights like skills, work history, social links, and more

Discover, research and enrich contacts with Highperformr — Smarter, Faster

Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.

Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.

  • Track signals like job change, promotion, and LinkedIn activity
  • Enrich contacts with verified email, phone, and social data instantly
  • Automate enrichment and updates with powerful workflows
  • Sync enriched contact info directly into your CRM and tools

Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.

Intent Signals

Buyer intent signals

CRM Enrichment

Contact Enrichment

Workflows and tasks

Workflows and tasks

Integrations

Integrations

Thousands of companies, including, are just a search away.